Travere Therapeutics, Inc. is a US-based pharmaceutical company with a medium-risk ESG score of 28.5. Specializing in rare kidney, liver, and metabolic diseases, Travere Therapeutics is dedicated to creating life-changing therapies for its patients. One of their key pipeline candidates, sparsentan, is in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).